Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484

Journal of Clinical Oncology

Volumn 22, Issue 15, 2004, Pages 3032-3038

  Horning, Sandra J ^a   Weller, Edie ^a   Kim, KyungMann ^a   Earle, John D ^a   O'Connell, Michael J ^a   Habermann, Thomas M ^a   Glick, John H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; LYMPHOSARCOMA; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, DIFFUSE; MALE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; VINCRISTINE;

EID: 4143102674     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.088     Document Type: Article

References (21)

1. Kaminski MS, Coleman CN, Colby TV, et al: Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 104:747-756, 1986
2. Miller TP, Jones SE: Chemotherapy of localised histiocytic lymphoma. Lancet 1:358-360, 1979
3. Cabanillas F, Bodey GP, Freireich EJ: Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 46:2356-2359, 1980
4. Tondini C, Zanini M, Lombardi F, et al: Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non- Hodgkin's lymphomas. J Clin Oncol 11:720-725, 1993
5. Prestidge BR, Horning SJ, Hoppe RT: Combined modality therapy for stage I-II large cell lymphoma. Int J Radiat Oncol Biol Phys 15:633-639, 1988
6. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
7. Miller TP, LeBlanc M, Spier C, et al: CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood 98:724A, 2001 (abstr 3024)
8. Fillet G, Bonnet N, Mounier N, et al: Radiotherapy is unnecessary in elderly patients with localized aggressive non Hodgkin's lymphoma: Results of the GELA LNH 93-4 study. Proc Am Soc Hematol 100:92a, 2002 (abstr 337)
9. Reyes F, Lepage E. Munck JN, et al: Superiority of chemotherapy alone with the ACVBP regimen over treatment with three cycles of CHOP plus radiotherapy in low risk localized aggressive lymphoma: The LNH93-1 GELA study. Blood 100:93a, 2002 (abstr 343)
10. Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
11. Surbone A, Longo DL, DeVita VJ, et al: Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management. J Clin Oncol 6:1832-1837, 1988
12. Shenkier TN, Voss N, Fairey R, et al: Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20:197-204, 2002
13. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
14. Habermann T, Weller E, Morrison V, et al: Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma. Proc Am Soc Hematol:6a, 2003 (abstr 8)
15. Juweid ME: Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice. J Nucl Med 43:1507-1529, 2002
16. Kostakoglu L, Goldsmith SJ: Positron emission tomography in lymphoma: Comparison with computed tomography and Gallium-67 single photon emission computed tomography. Clin Lymphoma 1:67-76, 2000
17. Jerusalem G, Beguin Y, Fassotte MF, et al: Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85:613-618, 2000
18. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
19. Spaepen K, Stroobants S, Dupont P, et al: Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419, 2001
20. Rosenwald A, Wright G, Leroy K, et al: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851-862, 2003
21. Savage KJ, Monti S, Kutok JL, et al: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003